Relationship between cachexia and perineural invasion in pancreatic adenocarcinoma

doi:10.4251/wjgo.v11.i12.1126

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6246)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

366

WORD

208

HTML

2934

Figures (1-5)

255

Tables (1-4)

246

Sum=4009

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

889

Download

1348

Sum=2237

Dec 15, 2019 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Oncol. Dec 15, 2019; 11(12): 1126-1140
Published online Dec 15, 2019. doi: 10.4251/wjgo.v11.i12.1126

Table 1 Patient characteristics in the adenocarcinoma and control groups, n (%)

Characteristics	PDAC (n = 114)	Control (n = 125)
Age (yr), mean (SD)	64.76 (10.58)^b	60.26 (12.03)
Age > 50 yr	103 (90.35)^b	89 (71.2)
Sex (female)	47 (41.23)	46 (36.8)
BMI (kg/m²), median (IQR)	25.09 (22.05-27.25)	25.26 (22.58-28.72)
Weight status
Underweight	12 (10.53)	5 (4)
Normal	48 (42.11)	53 (42.4)
Overweight	37 (32.46)	44 (35.2)
Obesity	17 (14.91)	23 (18.4)
Smoking	50 (43.86)	69 (55.2)
New-onset diabetes	24 (21.05)^b	8 (6.4)
Long-term diabetes	24 (21.05)	32 (25.6)
Diabetes	49 (42.98)^a	38 (30.4)
CA 19-9 (U/mL), median (IQR)	400 (67.75-400)^b	31.45 (9.58-98.8)
Cachexia	22 (19)	8 (6)
T stage	1-2: 10 (8.85); 3: 65 (57.52); 4: 38 (33.63)
Histological grade	G1: 8/41 (19.51); G2: 24/41 (58.54); G3: 12/41 (29.27)
N stage	9 (8.18)
Metastasis	48 (42.11)

^aP < 0.05,

^bP < 0.01 vs controls. PDAC: Pancreatic ductal adenocarcinoma; BMI: Body-mass index; CA 19-9: Carbohydrate antigen 19-9; QR: Interquartile range; CI: Confidence interval.

Table 2 Protein plasma expression in adenocarcinoma patients and interaction with clinical and biological parameters, n (%)

Protein expression	Midkine		Activin
Protein expression	Low (n = 60)	High (n = 54)	Low (n = 42)	High (n = 72)
Age (yr), mean (SD)	63.02 (10.06)	66.7 (10.91)	63.64 (10.4)	65.42 (10.7)
BMI (kg/m²), median (IQR)	24.34 (20.71-26.54)	25.79 (23.11-27.52)^a	25.66 (22.24-27.52)	24.52 (22.05-26.94)
CA 19-9 (U/mL), median (IQR)	400 (53.5-400)	352 (70-400)	400 (53.5-400)	191 (70-400)
Age > 50 yr	53 (88.33)	50 (92.59)	36 (85.71)	67 (93.06)
Sex (female)	27 (45)	20 (37.04)	18 (42.86)	29 (40.28)
Stage (III-IV vs I-II)	28 (46.67)	39 (72.22)^b	20 (47.62)	47 (65.28)
Histological grade
G1	3 (16.67)	4 (17.39)	3 (16.67)	4 (17.39)
G2	10 (55.56)	12 (52.17)	13 (72.22)	9 (39.13)
G3	5 (27.78)	7 (30.43)	2 (11.11)	10 (43.48)
Metastasis	20 (33.33)	28 (51.85)^a	14 (33.33)	34 (47.22)
Tumor size ≥ 3 cm	44 (78.57)	43 (87.76)	30 (75)	57 (87.69)
Weight loss of 5% over the past 6 mo	45 (90)	29 (82.86)	11 (26)	23 (32)
Weight
Underweight	9 (15)	3 (5.56)	3 (7.14)	9 (12.5)
Normal	28 (46.67)	20 (37.04)	16 (38.1)	32 (44.44)
Overweight	15 (25)	22 (40.74)	14 (33.33)	23 (31.94)
Obesity	8 (13.33)	9 (16.67)		8 (11.11)
Smoking	32 (53.33)	18 (33.33)^a	17 (40.48)	33 (45.83)
New-onset diabetes	16 (26.67)	8 (14.81)	8 (19.05)	16 (22.22)
Long-term diabetes	6 (10)	18 (33.33)^b	10 (23.81)	14 (19.44)
Diabetes	22 (36.67)	27 (50)	18 (42.86)	31 (43.06)
IHC
Negative	36 (60)	22 (40.74)^a	29 (69.05)	26 (36.11)^b
Weak	18 (30)	16 (29.63)	11 (26.19)	42 (58.33)
Moderate	5 (8.33)	11 (20.37)	2 (4.76)	4 (5.56)
Strong	1 (1.67)	5 (9.26)
Immunohistochemistry perineural invasion (appearances on slide)	2: 3 (9.09); 0: 17 (51.52); 1: 13 (39.39)	2: 9 (32.14)^a; 0: 7 (25); 1: 12 (42.86)	2: 5 (17.86); 0: 13 (46.43); 1: 10 (35.71)	2: 7 (21.21); 0: 11 (33.33); 1: 15 (45.45)
Cachexia	16 (73)	6 (27)	15 (26)	7 (32)

^aP < 0.05,

^bP < 0.01. BMI: Body-mass index; CA 19-9: Carbohydrate antigen; IHC: Immunohistochemistry; IQR: Interquartile range; CI: Confidence interval.

Table 3 Univariate and multivariate analysis to predict metastasis

	Univariate analyses			Multivariate analyses
	OR unadjusted	95%CI	P value	OR unadjusted	95%CI	P value
Age > 50 yr	0.95	0.23-4.16	0.942	1.24	0.33-5.2	0.75
Sex (male vs female)	1.25	0.53-2.99	0.617	1.27	0.56-2.91	0.571
N1	2.04	0.53-10.09	0.326	2.27	0.61-10.92	0.251
Tumor size ≥ 3 cm	0.87	0.28-2.8	0.809	1.13	0.4-3.39	0.821
Midkine expression (high-expressed vs low-expressed)	2.12	0.92-5	0.08	1.92	0.87-4.33	0.11
Activin expression (high-expressed vs low-expressed)	1.94	0.78-5.01	0.157	1.62	0.71-3.81	0.261

OR: Odds ratio; HR: Hazard ratio; CI: Confidence interval.

Table 4 Univariate and multivariate analysis to predict survival

	Univariate analyses			Multivariate analyses
	HR adjusted	95%CI	P value	HR adjusted	95%CI	P value
Age > 50 yrs	2.43	1.18-5.01	0.016	1.9	0.86-4.2	0.113
Sex (male vs female)	0.51	0.34-0.76	0.001	0.66	0.42-1.05	0.078
N1	1.42	0.74-2.73	0.299	1.13	0.54-2.36	0.745
Tumor size ≥ 3 cm	2.13	1.13-4.01	0.02	2.36	1.21-4.62	0.012
Metastases	2.09	1.4-3.12	< 0.001	1.62	1.01-2.62	0.047
Midkine expression (high-expressed vs low-expressed)	1.67	1.12-2.48	0.011	0.76	0.48-1.2	0.24
Activin expression (high-expressed vs low-expressed)	3.61	2.34-5.56	< 0.001	1.98	1.2-3.27	0.008

OR: Odds ratio; HR: Hazard ratio; CI: Confidence interval.

Citation: Petrusel L, Rusu I, Leucuta DC, Seicean R, Suharoschi R, Zamfir P, Seicean A. Relationship between cachexia and perineural invasion in pancreatic adenocarcinoma. World J Gastrointest Oncol 2019; 11(12): 1126-1140
URL: https://www.wjgnet.com/1948-5204/full/v11/i12/1126.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i12.1126